Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Novo Nordisk A/SNYSE: NVO

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of DKK 34.33B rose 12.3% year over year, ahead of the +3.8% change in trailing-twelve-month operating expenses. Sequentially, it rose 45.4% from the prior quarter. Over 3 fiscal years it compounded at +18.5% a year.

Context

  • Operating expenses amounted to 39.7% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.3% holds above the trailing-twelve-month pace of +3.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 34.33B+45.4% QoQ
Last fiscal yearDec 2025
DKK 122.62B+4.3% YoY
LTMJun 2026
DKK 123.58B+3.8% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%——
1 year+4.3%——
3-year CAGR+18.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

DKK · from the income statement

Latest · FY2025
122.62B DKK
Year-over-year change
+4.3%
4-year CAGR
+20.3%

Operating Expenses vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.8% is the 6th highest of 10, against a peer median of +5.1%.
  • Operating expenses amounts to 37.5% of revenue for NVO, versus a peer median of 46.5%.
NVO Competitors
Operating Expenses for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 123.58B DKK+3.8%+18.5%37.5%
JNJJohnson & JohnsonLTM Sep 2026$42.83B USD+10.7%+3.7%43.1%
MRKMerck & Co., Inc.LTM Jun 2026$38.99B USD+46.3%-0.5%58.7%
AZNAstraZeneca PLCLTM Sep 2026$35.08B USD-0.0%+6.8%56.4%
PFEPfizer Inc.LTM Jun 2026$29.59B USD+0.7%+0.5%46.5%
SNYSanofiLTM Jun 2026€28.48B EUR+24.0%+9.1%58.2%
ABBVAbbVie Inc.LTM Sep 2026$26.88B USD-17.4%+0.5%40.7%
LLYEli Lilly and CompanyLTM Jun 2026$26.83B USD+24.4%+22.6%33.7%
GSKGSK plcLTM Jun 2026£17.27B GBP-1.0%+4.7%52.0%
AMGNAmgen Inc.LTM Jun 2026$15.05B USD+5.1%+14.0%39.5%
Peer median (excluding NVO) —+5.1%+4.7%46.5%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.